Results 1 to 10 of about 48,643 (117)

Co-stimulatory signal deficiency impairs cytotoxic T lymphocyte function in tumor immune evasion: molecular mechanisms and therapeutic implications [PDF]

Journal of Translational Medicine
The generation and maintenance of effective tumor-specific CTL responses require more than antigen recognition. In most settings, TCR engagement must be accompanied by co-stimulatory input, with the B7-1/B7-2–CD28 axis being one of the best-characterized
Junjie Ma, Jing Chen, Tianrun Miao, Yehong Li, Yongmeng Li, Lei Zhao, Hui Tian   +6 more
doaj   +2 more sources

CAR T-cell therapy in pediatric brain tumors: a narrative review with comparative analysis of clinical trial eligibility criteria [PDF]

Frontiers in Oncology
Pediatric brain tumors are the leading cause of cancer-related mortality in children, and current standard therapies like surgery, radiotherapy, and chemotherapy offer limited survival benefits and significant long-term morbidity.
Akshaya Srinivasan, Angeline Abraham, Aliya I. Modak, Anugrah Pradeep, Nisrine L. Nimachwala, Akshit V. Chemmancheri, Aarifa Banu, Afnan A. Azad, Ashly Abraham, Lika Khorbaladze   +9 more
doaj   +2 more sources

Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy [PDF]

Cell Reports Medicine
Summary: B7-H3 is a cell surface protein overexpressed in many solid tumors and an attractive target for chimeric antigen receptor (CAR) T cell therapy.
Pradip Bajgain, Yang Feng, Mariela Puebla, Meijie Tian, Kuo-Sheng Hsu, Jaewon Lee, GuoJun Yu, Liping Yang, Steven Seaman, Mary Beth Hilton, Karen Morris, Niza Borchin, Jennifer D. Tran, Riley D. Metcalfe, Dan Li, Mitchell Ho, James C. Cronk, Javed Khan, Anandani Nellan, Rosandra N. Kaplan, Brad St. Croix   +20 more
doaj   +2 more sources

Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase. [PDF]

PLoS ONE, 2014
The association of B7-1/CD28 between antigen presenting cells (APCs) and T-cells provides a second signal to proliferate and activate T-cell immunity at the induction phase.
Xiao-Lin Li, Marjolein Sluijter, Elien M Doorduijn, Shubha P Kale, Harris McFerrin, Yong-Yu Liu, Yan Li, Madhusoodanan Mottamal, Xin Yao, Fengkun Du, Baihan Gu, Kim Hoang, Yen H Nguyen, Nichelle Taylor, Chelsea R Stephens, Thorbald van Hall, Qian-Jin Zhang   +16 more
doaj   +1 more source

Alternative immune checkpoints in immunoregulatory profile of cancer stem cells

Heliyon, 2023
Tumor-mediated bypass of immune checkpoint inhibitor (ICI) therapy with anti-programmed death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1, also called B7–H1 or CD274) or anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is a challenge of ...
Keywan Mortezaee, Jamal Majidpoor
doaj   +1 more source

Augmented Innate and Adaptive Immune Responses Under Conditions of Diabetes–Filariasis Comorbidity

Frontiers in Immunology, 2021
Metainflammation, as seen in chronic diabetes subjects, impairs immunity and increases the susceptibility to infections. In the present study, the effect of diabetes on immune response against filariasis was studied.
Joy Manohar Sibi, Viswanathan Mohan, Saravanan Munisankar, Subash Babu, Vivekanandhan Aravindhan   +4 more
doaj   +1 more source

The homodimer interfaces of costimulatory receptors B7 and CD28 control their engagement and pro-inflammatory signaling

Journal of Biomedical Science, 2023
Background The inflammatory response is indispensable for protective immunity, yet microbial pathogens often trigger an excessive response, ‘cytokine storm’, harmful to the host. Full T-cell activation requires interaction of costimulatory receptors B7-1(
Andrey Popugailo, Ziv Rotfogel, Michal Levy, Orli Turgeman, Dalia Hillman, Revital Levy, Gila Arad, Tomer Shpilka, Raymond Kaempfer   +8 more
doaj   +1 more source

B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models

OncoImmunology, 2020
The application of chimeric antigen receptor (CAR)-T cell therapy in patients with advanced solid tumors remains a significant challenge. Simultaneously targeting antigen and the solid tumor microenvironment are two major factors that greatly impact CAR ...
Baozhu Huang, Liqun Luo, Jun Wang, Bailin He, Rui Feng, Na Xian, Qiong Zhang, Lieping Chen, Gangxiong Huang   +8 more
doaj   +1 more source

Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma

Translational Oncology, 2020
Extranodal nasal natural killer (NK)/T cell lymphoma (ENKTCL) is a rare but highly aggressive subtype of non-Hodgkin lymphoma (NHL). Nevertheless, despite extensive research, the estimated 5-year overall survival of affected patients remains low ...
Meijun Zheng, Lingyu Yu, Juanjuan Hu, Zongliang Zhang, Haiyang Wang, Dan Lu, Xin Tang, Jianhan Huang, Kunhong Zhong, Zeng Wang, Yisong Li, Gang Guo, Shixi Liu, Aiping Tong, Hui Yang   +14 more
doaj   +1 more source

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Journal of Experimental & Clinical Cancer Research, 2021
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) are two most representative immune checkpoint pathways, which negatively regulate T cell immune function during different ...
Hao Zhang, Ziyu Dai, Wantao Wu, Zeyu Wang, Nan Zhang, Liyang Zhang, Wen-Jing Zeng, Zhixiong Liu, Quan Cheng   +8 more
doaj   +1 more source